COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).

[1]  M. Decramer,et al.  Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. , 2004, Chest.

[2]  I. Adcock,et al.  Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction , 2008, European Respiratory Journal.

[3]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[4]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[5]  J. Zieliński,et al.  Prevalence, severity and underdiagnosis of COPD in the primary care setting , 2008, Thorax.

[6]  M. Decramer,et al.  Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial , 2009, European Respiratory Journal.

[7]  Kourtney J. Davis,et al.  Lung function decline and outcomes in an elderly population , 2006, Thorax.

[8]  T. Takishima,et al.  Underdiagnosis and undertreatment of COPD in primary care settings , 2003, Respirology.

[9]  D. Jarvis,et al.  Long-term outcomes in mild/moderate chronic obstructive pulmonary disease in the European community respiratory health survey. , 2009, American journal of respiratory and critical care medicine.

[10]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[11]  A. Morice,et al.  An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) , 1997, The European respiratory journal.

[12]  F Neukirch,et al.  An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages , 2004, Thorax.

[13]  D. Postma,et al.  Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[14]  M. Decramer,et al.  Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[15]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[16]  M. Decramer,et al.  Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial , 2009, The Lancet.

[17]  P. Sullivan,et al.  The types of regular cigarette smokers: a latent class analysis. , 2005, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[18]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[19]  D. Mannino.  Women and chronic obstructive pulmonary disease: does sex influence survival? , 2006, American journal of respiratory and critical care medicine.

[20]  D. Mannino,et al.  Lung function decline and outcomes in an adult population. , 2006, American journal of respiratory and critical care medicine.

[21]  D. Postma,et al.  Airways inflammation and treatment during acute exacerbations of COPD , 2008, International journal of chronic obstructive pulmonary disease.

[22]  J. Strausz,et al.  Pathology of chronic obstructive pulmonary disease , 2006, Pathology & Oncology Research.

[23]  D. Mannino,et al.  Global burden of COPD: risk factors, prevalence, and future trends , 2007, The Lancet.